Pharmacokinetic model analysis of the interaction between phenytoin and capecitabine

Shohei Miyazaki, Hiroki Satoh, Masayuki Ikenishi, Miyuki Sakurai, Mutsuaki Ueda, Kaori Kawahara, Rie Ueda, Tohru Ohtori, Kenji Matsuyama, Akiko Miki, Satoko Hori, Eiji Fukui, Eitaro Nakatsuka, Yasufumi Sawada

研究成果: Article

3 引用 (Scopus)

抄録

Objective: Recent reports have shown an increase in serum phenytoin levels resulting in phenytoin toxicity after initiation of fluoropyrimidine chemotherapy. To prevent phenytoin intoxication, phenytoin dosage must be adjusted. We sought to develop a pharmacokinetic model of the interaction between phenytoin and capecitabine. Methods: We developed the phenytoin-capecitabine interaction model on the assumption that fluorouracil (5-FU) inhibits cytochrome P450 (CYP) 2C9 synthesis in a concentration-dependent manner. The plasma 5-FU concentration after oral administration of capecitabine was estimated using a conventional compartment model. Nonlinear pharmacokinetics of phenytoin was modeled by incorporating the Michaelis-Menten equation to represent the saturation of phenytoin metabolism. The resulting model was fitted to data from our previously-reported cases. Results: The developed phenytoincapecitabine interaction model successfully described the profiles of serum phenytoin concentration in patients who received phenytoin and capecitabine concomitantly. The 50% inhibitory 5-FU concentration for CYP2C9 synthesis and the degradation rate constant of CYP2C9 were estimated to be 0.00310 ng/mL and 0.0768 day-1, respectively. This model and these parameters allow us to predict the appropriate phenytoin dosage schedule when capecitabine is administered concomitantly. Conclusions: This newly-developed model accurately describes changes in phenytoin concentration during concomitant capecitabine chemotherapy, and it may be clinically useful for predicting appropriate phenytoin dosage adjustments for maintaining serum phenytoin levels within the therapeutic range.

元の言語English
ページ(範囲)657-665
ページ数9
ジャーナルInternational Journal of Clinical Pharmacology and Therapeutics
54
発行部数9
DOI
出版物ステータスPublished - 2016 9 1
外部発表Yes

Fingerprint

Phenytoin
Pharmacokinetics
Fluorouracil
Capecitabine
Serum
Drug Therapy
Cytochrome P-450 Enzyme System
Oral Administration
Appointments and Schedules

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

これを引用

Pharmacokinetic model analysis of the interaction between phenytoin and capecitabine. / Miyazaki, Shohei; Satoh, Hiroki; Ikenishi, Masayuki; Sakurai, Miyuki; Ueda, Mutsuaki; Kawahara, Kaori; Ueda, Rie; Ohtori, Tohru; Matsuyama, Kenji; Miki, Akiko; Hori, Satoko; Fukui, Eiji; Nakatsuka, Eitaro; Sawada, Yasufumi.

:: International Journal of Clinical Pharmacology and Therapeutics, 巻 54, 番号 9, 01.09.2016, p. 657-665.

研究成果: Article

Miyazaki, S, Satoh, H, Ikenishi, M, Sakurai, M, Ueda, M, Kawahara, K, Ueda, R, Ohtori, T, Matsuyama, K, Miki, A, Hori, S, Fukui, E, Nakatsuka, E & Sawada, Y 2016, 'Pharmacokinetic model analysis of the interaction between phenytoin and capecitabine', International Journal of Clinical Pharmacology and Therapeutics, 巻. 54, 番号 9, pp. 657-665. https://doi.org/10.5414/CP202416
Miyazaki, Shohei ; Satoh, Hiroki ; Ikenishi, Masayuki ; Sakurai, Miyuki ; Ueda, Mutsuaki ; Kawahara, Kaori ; Ueda, Rie ; Ohtori, Tohru ; Matsuyama, Kenji ; Miki, Akiko ; Hori, Satoko ; Fukui, Eiji ; Nakatsuka, Eitaro ; Sawada, Yasufumi. / Pharmacokinetic model analysis of the interaction between phenytoin and capecitabine. :: International Journal of Clinical Pharmacology and Therapeutics. 2016 ; 巻 54, 番号 9. pp. 657-665.
@article{cec88b70e62542be80f2dafbc05da1ab,
title = "Pharmacokinetic model analysis of the interaction between phenytoin and capecitabine",
abstract = "Objective: Recent reports have shown an increase in serum phenytoin levels resulting in phenytoin toxicity after initiation of fluoropyrimidine chemotherapy. To prevent phenytoin intoxication, phenytoin dosage must be adjusted. We sought to develop a pharmacokinetic model of the interaction between phenytoin and capecitabine. Methods: We developed the phenytoin-capecitabine interaction model on the assumption that fluorouracil (5-FU) inhibits cytochrome P450 (CYP) 2C9 synthesis in a concentration-dependent manner. The plasma 5-FU concentration after oral administration of capecitabine was estimated using a conventional compartment model. Nonlinear pharmacokinetics of phenytoin was modeled by incorporating the Michaelis-Menten equation to represent the saturation of phenytoin metabolism. The resulting model was fitted to data from our previously-reported cases. Results: The developed phenytoincapecitabine interaction model successfully described the profiles of serum phenytoin concentration in patients who received phenytoin and capecitabine concomitantly. The 50{\%} inhibitory 5-FU concentration for CYP2C9 synthesis and the degradation rate constant of CYP2C9 were estimated to be 0.00310 ng/mL and 0.0768 day-1, respectively. This model and these parameters allow us to predict the appropriate phenytoin dosage schedule when capecitabine is administered concomitantly. Conclusions: This newly-developed model accurately describes changes in phenytoin concentration during concomitant capecitabine chemotherapy, and it may be clinically useful for predicting appropriate phenytoin dosage adjustments for maintaining serum phenytoin levels within the therapeutic range.",
keywords = "Capecitabine, Drug interactions, Pharmacokinetic model analysis, Phenytoin",
author = "Shohei Miyazaki and Hiroki Satoh and Masayuki Ikenishi and Miyuki Sakurai and Mutsuaki Ueda and Kaori Kawahara and Rie Ueda and Tohru Ohtori and Kenji Matsuyama and Akiko Miki and Satoko Hori and Eiji Fukui and Eitaro Nakatsuka and Yasufumi Sawada",
year = "2016",
month = "9",
day = "1",
doi = "10.5414/CP202416",
language = "English",
volume = "54",
pages = "657--665",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "9",

}

TY - JOUR

T1 - Pharmacokinetic model analysis of the interaction between phenytoin and capecitabine

AU - Miyazaki, Shohei

AU - Satoh, Hiroki

AU - Ikenishi, Masayuki

AU - Sakurai, Miyuki

AU - Ueda, Mutsuaki

AU - Kawahara, Kaori

AU - Ueda, Rie

AU - Ohtori, Tohru

AU - Matsuyama, Kenji

AU - Miki, Akiko

AU - Hori, Satoko

AU - Fukui, Eiji

AU - Nakatsuka, Eitaro

AU - Sawada, Yasufumi

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Objective: Recent reports have shown an increase in serum phenytoin levels resulting in phenytoin toxicity after initiation of fluoropyrimidine chemotherapy. To prevent phenytoin intoxication, phenytoin dosage must be adjusted. We sought to develop a pharmacokinetic model of the interaction between phenytoin and capecitabine. Methods: We developed the phenytoin-capecitabine interaction model on the assumption that fluorouracil (5-FU) inhibits cytochrome P450 (CYP) 2C9 synthesis in a concentration-dependent manner. The plasma 5-FU concentration after oral administration of capecitabine was estimated using a conventional compartment model. Nonlinear pharmacokinetics of phenytoin was modeled by incorporating the Michaelis-Menten equation to represent the saturation of phenytoin metabolism. The resulting model was fitted to data from our previously-reported cases. Results: The developed phenytoincapecitabine interaction model successfully described the profiles of serum phenytoin concentration in patients who received phenytoin and capecitabine concomitantly. The 50% inhibitory 5-FU concentration for CYP2C9 synthesis and the degradation rate constant of CYP2C9 were estimated to be 0.00310 ng/mL and 0.0768 day-1, respectively. This model and these parameters allow us to predict the appropriate phenytoin dosage schedule when capecitabine is administered concomitantly. Conclusions: This newly-developed model accurately describes changes in phenytoin concentration during concomitant capecitabine chemotherapy, and it may be clinically useful for predicting appropriate phenytoin dosage adjustments for maintaining serum phenytoin levels within the therapeutic range.

AB - Objective: Recent reports have shown an increase in serum phenytoin levels resulting in phenytoin toxicity after initiation of fluoropyrimidine chemotherapy. To prevent phenytoin intoxication, phenytoin dosage must be adjusted. We sought to develop a pharmacokinetic model of the interaction between phenytoin and capecitabine. Methods: We developed the phenytoin-capecitabine interaction model on the assumption that fluorouracil (5-FU) inhibits cytochrome P450 (CYP) 2C9 synthesis in a concentration-dependent manner. The plasma 5-FU concentration after oral administration of capecitabine was estimated using a conventional compartment model. Nonlinear pharmacokinetics of phenytoin was modeled by incorporating the Michaelis-Menten equation to represent the saturation of phenytoin metabolism. The resulting model was fitted to data from our previously-reported cases. Results: The developed phenytoincapecitabine interaction model successfully described the profiles of serum phenytoin concentration in patients who received phenytoin and capecitabine concomitantly. The 50% inhibitory 5-FU concentration for CYP2C9 synthesis and the degradation rate constant of CYP2C9 were estimated to be 0.00310 ng/mL and 0.0768 day-1, respectively. This model and these parameters allow us to predict the appropriate phenytoin dosage schedule when capecitabine is administered concomitantly. Conclusions: This newly-developed model accurately describes changes in phenytoin concentration during concomitant capecitabine chemotherapy, and it may be clinically useful for predicting appropriate phenytoin dosage adjustments for maintaining serum phenytoin levels within the therapeutic range.

KW - Capecitabine

KW - Drug interactions

KW - Pharmacokinetic model analysis

KW - Phenytoin

UR - http://www.scopus.com/inward/record.url?scp=84984677204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984677204&partnerID=8YFLogxK

U2 - 10.5414/CP202416

DO - 10.5414/CP202416

M3 - Article

C2 - 27390048

AN - SCOPUS:84984677204

VL - 54

SP - 657

EP - 665

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 9

ER -